# Colorectal Cancer Screening > Colorectal cancer screening for NEET-PG Surgery: FIT, colonoscopy, guaiac FOBT evidence, adenoma-carcinoma sequence and Indian programme status. - Canonical URL: https://prepelephant.com/topics/neet-pg/surgery/colorectal-cancer-screening - Exam / course: NEET-PG · Subject: Surgery - Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team - First published: 2026-10-02 - Last updated: 2026-10-02 - How to cite: "Colorectal Cancer Screening", PrepElephant, https://prepelephant.com/topics/neet-pg/surgery/colorectal-cancer-screening ## Direct answer India runs no organised national colorectal cancer screening programme — screening in Indian practice is opportunistic and clinician-initiated, which makes the mechanics worth knowing precisely. In average-risk Western populations, screening begins at 45 (United States) or 50 years, with options including annual faecal immunochemical test (FIT), colonoscopy every 10 years, flexible sigmoidoscopy or CT colonography every 5 years, and stool DNA-FIT every 1 to 3 years. The guaiac faecal occult blood test remains the only modality with randomised-trial mortality reduction; colonoscopy offers the longest interval and same-session polypectomy. Any positive stool test earns a full colonoscopy. The roughly ten-year adenoma-to-carcinoma dwell time is the biological fact that makes every one of these schedules work. ## What you must remember - **Average risk defined:** no personal or family history of colorectal neoplasia and no alarm features; Western start age 45–50, Indian practice screens opportunistically with high-risk groups prioritised. - **Modality menu:** annual FIT, colonoscopy 10-yearly, flexible sigmoidoscopy 5-yearly, CT colonography 5-yearly, stool DNA-FIT every 1–3 years. - **Evidence hierarchy:** guaiac FOBT is the only modality proven in randomised trials (Minnesota and European studies) to reduce mortality; colonoscopy data are observational plus emerging trial evidence of reduced cancer mortality in screened men. - **FIT advantages:** immunochemical, no dietary restriction, better sensitivity than guaiac for lower bleeding thresholds. - **The 10-year logic:** the APC–KRAS–p53 adenoma–carcinoma sequence takes about 8–10 years, licensing 10-yearly colonoscopy after a normal study. - **Positive FIT action:** colonoscopy — a repeat negative test never overrides a positive first result. - **Hereditary flags:** Amsterdam and Bethesda criteria for Lynch syndrome (about 3 percent of colorectal cancer) and hundreds of adenomas in FAP shift relatives into intense, early surveillance pathways. - **Rising early-onset disease:** colorectal cancer under 50 is rising globally and visible in Indian referral centres — rectal bleeding in a 38-year-old is never "just piles" until examined. ## A worked screening pathway A symptomless 52-year-old asks what he should do. Average risk, so the menu is annual FIT or a one-off screening colonoscopy with 10-year protection if normal. He chooses colonoscopy; two tubular adenomas under 10 mm are removed, and he now exits screening into polyp surveillance at 7–10 years. Three other consultations from the same week complete the picture: his colleague with a positive FIT from a health camp proceeds directly to colonoscopy whatever a repeat test shows; a 42-year-old whose father had colorectal cancer at 55 starts colonoscopic surveillance at 40, or 10 years before the relative's diagnosis, repeated 5-yearly; and a 30-year-old with cancers across three generations, one diagnosed under 50, triggers Lynch suspicion — mismatch-repair immunohistochemistry and germline testing, with 1–2 yearly colonoscopy if confirmed. Screening, surveillance and hereditary programmes are three separate clocks, and the exam tests whether you know which one a given patient is on. ## How the exam frames it Recurring questions ask which modality has randomised-trial mortality evidence (guaiac FOBT), the interval after a normal colonoscopy (10 years), and the next step after a positive FIT (colonoscopy — "repeat the test" is the planted distractor). The adenoma–carcinoma dwell time links screening policy to molecular biology, a favourite integration across subjects. The Indian framing adds a programme fact worth one guaranteed mark: colorectal cancer screening is not part of India's national NCD and cancer control programmes, so average-risk Indian questions are answered with opportunistic screening logic rather than programme recall. ## Frequently asked questions ### At what age does average-risk colorectal cancer screening begin? At 45 years under current US guidance and 50 in most European and Indian practice, continuing while life expectancy remains adequate — to about 75 in the US framework. ### Which screening test has randomised-trial evidence of mortality reduction? The guaiac faecal occult blood test, in trials such as Minnesota and the European FOBT studies; FIT and colonoscopy rest on strong observational and emerging trial data. ### What follows a positive faecal immunochemical test? A complete colonoscopy with polypectomy — a negative repeat FIT never overrides a positive first test. ### Why is colonoscopy repeated only every 10 years when normal? The adenoma-to-carcinoma sequence takes on average 8–10 years, so a clean baseline colonoscopy protects for roughly a decade. ### When should screening start for someone with one first-degree relative affected at 55? At age 40, or 10 years before the relative's age at diagnosis, with colonoscopy preferred and repeated every 5 years.